Eyepoint Pharmaceuticals Inc (NASDAQ:EYPT)’s share price traded up 9% during trading on Tuesday . The company traded as high as $1.00 and last traded at $1.00, 633,700 shares were traded during trading. A decline of 24% from the average session volume of 831,688 shares. The stock had previously closed at $0.92.

A number of analysts recently commented on the company. ValuEngine upgraded Eyepoint Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Wednesday. Zacks Investment Research upgraded Eyepoint Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.25 target price for the company in a report on Thursday, January 30th. Finally, HC Wainwright reiterated a “hold” rating on shares of Eyepoint Pharmaceuticals in a report on Tuesday, March 3rd. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $3.95.

The stock has a market capitalization of $123.50 million, a P/E ratio of -1.77 and a beta of 1.76. The stock has a 50 day moving average of $1.41 and a 200 day moving average of $1.67. The company has a debt-to-equity ratio of 6.02, a quick ratio of 3.44 and a current ratio of 3.62.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last issued its quarterly earnings data on Thursday, March 5th. The company reported ($0.10) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.12) by $0.02. Eyepoint Pharmaceuticals had a negative return on equity of 285.39% and a negative net margin of 278.89%. The firm had revenue of $8.63 million during the quarter, compared to the consensus estimate of $7.70 million. On average, research analysts anticipate that Eyepoint Pharmaceuticals Inc will post -0.32 EPS for the current fiscal year.

In other Eyepoint Pharmaceuticals news, CEO Nancy Lurker purchased 98,000 shares of the firm’s stock in a transaction dated Tuesday, March 10th. The stock was bought at an average price of $1.06 per share, with a total value of $103,880.00. Following the completion of the purchase, the chief executive officer now owns 574,800 shares in the company, valued at approximately $609,288. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Corporate insiders own 41.29% of the company’s stock.

Large investors have recently added to or reduced their stakes in the company. Citigroup Inc. lifted its holdings in shares of Eyepoint Pharmaceuticals by 293.6% in the fourth quarter. Citigroup Inc. now owns 21,027 shares of the company’s stock valued at $33,000 after buying an additional 15,685 shares during the period. Goldman Sachs Group Inc. lifted its holdings in shares of Eyepoint Pharmaceuticals by 32.9% during the fourth quarter. Goldman Sachs Group Inc. now owns 80,703 shares of the company’s stock valued at $125,000 after purchasing an additional 20,001 shares during the last quarter. Geode Capital Management LLC lifted its stake in Eyepoint Pharmaceuticals by 3.7% in the 4th quarter. Geode Capital Management LLC now owns 820,231 shares of the company’s stock worth $1,271,000 after acquiring an additional 29,252 shares in the last quarter. Barclays PLC lifted its stake in Eyepoint Pharmaceuticals by 93.5% in the 4th quarter. Barclays PLC now owns 63,060 shares of the company’s stock worth $98,000 after acquiring an additional 30,473 shares in the last quarter. Finally, Essex Investment Management Co. LLC lifted its stake in Eyepoint Pharmaceuticals by 4.9% in the 4th quarter. Essex Investment Management Co. LLC now owns 824,310 shares of the company’s stock worth $1,278,000 after acquiring an additional 38,665 shares in the last quarter. 50.26% of the stock is owned by institutional investors.

Eyepoint Pharmaceuticals Company Profile (NASDAQ:EYPT)

EyePoint Pharmaceuticals, Inc, a specialty biopharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States and Europe. It provides ILUVIEN for the treatment of diabetic macular edema; YUTIQ, a non-erodible fluocinolone acetonide insert for the treatment of non-infectious posterior uveitis (NIPU) that is in the Phase III clinical trials; and Retisert (fluocinolone acetonide intravitreal implant), a sustained-release implant for the treatment of posterior segment uveitis.

Read More: Trading Ex-Dividend Strategy

Receive News & Ratings for Eyepoint Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyepoint Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.